Login / Signup

Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.

Juan José LluchY José Manuel CarrascosaAlicia González-QuesadaRaquel Rivera-DíazAntonio Sahuquillo-TorralbaMar Llamas-VelascoFrancisco José Gómez-GarcíaEnrique Herrera-AcostaPablo de la CuevaOfelia Baniandrés-RodríguezJose Luis Lopez-EstebaranzIsabel BelinchónMarta FerránAlmudena MateuLourdes RodríguezJosep Riera-MonroigM Teresa Abalde-PintosGregorio CarreteroCarmen García-DonosoConrad Pujol-MarcoElena Del AlcázarCristina Santamaría-DomínguezJorge Alonso Suárez-PérezLula María Nieto-BenitoDiana Patricia Ruiz-GenaoLaura Salgado-BoqueteMiguel Ángel DescalzoIgnacio García-Doval
Published in: The British journal of dermatology (2023)
The risk of AEs and SAEs was not significantly increased in patients with moderate to severe psoriasis receiving different classes of biologic drugs plus MTX compared to those on biologic monotherapy.
Keyphrases
  • rheumatoid arthritis
  • high intensity
  • early onset
  • drug induced
  • high dose
  • atopic dermatitis
  • stem cells
  • study protocol
  • double blind